Novartis AG ADR (NVS)vsOnconetix Inc (ONCO)
NVS
Novartis AG ADR
$153.27
+0.76%
HEALTHCARE · Cap: $291.32B
ONCO
Onconetix Inc
$1.01
+20.42%
HEALTHCARE · Cap: $3.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7711135% more annual revenue ($56.69B vs $735,200). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
ONCO
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.5%
Fair Value
$92.73
Current Price
$153.27
$60.54 premium
Intrinsic value data unavailable for ONCO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -82.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : ONCO
The strongest argument for ONCO centers on Price/Book, Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : ONCO
The primary concerns for ONCO are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ONCO carries more volatility with a beta of 2.68 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 25/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Onconetix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Onconetix Inc. is a cutting-edge biotechnology firm committed to revolutionizing cancer care with its innovative diagnostic and therapeutic solutions. Utilizing a proprietary technology platform, the company specializes in early detection and personalized treatment for a range of malignancies, addressing key unmet needs in the oncology space. With a strong and diverse product pipeline, Onconetix is well-positioned to capitalize on the increasing demand for effective cancer therapies, aiming to significantly improve patient outcomes through its advanced research and development efforts in this dynamic and rapidly advancing field.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?